Silvy Laporte

Summary

Country: France

Publications

  1. doi Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients
    Silvy Laporte
    Dept of Clinical Pharmacology Hospital of Saint Etienne, France
    Thromb Res 130:853-8. 2012
  2. doi Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry
    Silvy Laporte
    Clinical Pharmacology Department, Thrombosis Research Group, EA 3065, University Hospital of Saint Etienne Bellevue, 42055 Saint Etienne Cedex 02, France
    Circulation 117:1711-6. 2008
  3. doi Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment model
    Silvy Laporte
    University Jean Monnet Saint Etienne, EA3065, Saint Etienne, France
    Crit Care Med 38:S10-7. 2010
  4. doi Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients
    S Laporte
    Universite de Lyon, Université Jean Monnet, Saint Etienne, France
    J Thromb Haemost 9:464-72. 2011
  5. ncbi Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial
    Silvy Laporte
    Thrombosis Research Group, Clinical Pharmacological Department, University Hospital, Pavillon 5, F 42055 Saint Etienne Cedex 2, France
    Thromb Haemost 89:458-67. 2003
  6. doi Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study
    Patrick Mismetti
    EA3065 Université Jean Monnet, Saint Etienne, Service de Médecine et Thérapeutique, Unite de Pharmacologie Clinique, CHU Saint Etienne, France
    Thromb Haemost 107:1151-60. 2012
  7. ncbi Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery
    Xavier Delavenne
    Thrombosis Research Group EA 3065, University Jean Monnet, 42023, Saint Etienne, France
    Eur J Clin Pharmacol 68:1403-10. 2012
  8. ncbi Investigation of drug-drug interactions between clopidogrel and fluoxetine
    Xavier Delavenne
    Laboratoire de Pharmacologie Toxicologie, CHU Saint Etienne, F 42055, Saint Etienne, France Université de Lyon, F 42023, Saint Etienne, France Groupe de Recherche sur la Thrombose, EA3065, Universite de Saint Etienne, Jean Monnet, F 42023, Saint Etienne, France
    Fundam Clin Pharmacol 27:683-9. 2013
  9. pmc Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry
    Laurent Bertoletti
    Thrombosis Research Group, EA3065, University Saint Etienne, Jean Monnet, Saint Etienne F 42023, France
    Respir Res 14:75. 2013
  10. doi Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice
    Xavier Delavenne
    Thrombosis Research Group EA 3065, University Jean Monnet, Saint Etienne, France
    Thromb Haemost 104:252-60. 2010

Detail Information

Publications46

  1. doi Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients
    Silvy Laporte
    Dept of Clinical Pharmacology Hospital of Saint Etienne, France
    Thromb Res 130:853-8. 2012
    ....
  2. doi Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry
    Silvy Laporte
    Clinical Pharmacology Department, Thrombosis Research Group, EA 3065, University Hospital of Saint Etienne Bellevue, 42055 Saint Etienne Cedex 02, France
    Circulation 117:1711-6. 2008
    ..Clinical predictors for fatal pulmonary embolism (PE) in patients with venous thromboembolism have never been studied...
  3. doi Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment model
    Silvy Laporte
    University Jean Monnet Saint Etienne, EA3065, Saint Etienne, France
    Crit Care Med 38:S10-7. 2010
    ..This article reviews evidence on the risk of venous thromboembolism associated with different medical conditions and risk factors, and presents a tentative risk-assessment model for risk stratification in hospitalized medical patients...
  4. doi Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients
    S Laporte
    Universite de Lyon, Université Jean Monnet, Saint Etienne, France
    J Thromb Haemost 9:464-72. 2011
    ..Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are both recommended for venous thromboembolism (VTE) prophylaxis in hospitalized medical patients...
  5. ncbi Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial
    Silvy Laporte
    Thrombosis Research Group, Clinical Pharmacological Department, University Hospital, Pavillon 5, F 42055 Saint Etienne Cedex 2, France
    Thromb Haemost 89:458-67. 2003
    ..No difference was found between the education groups. In patients starting oral anticoagulant therapy, dose determination may be the most important factor contributing to instability...
  6. doi Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study
    Patrick Mismetti
    EA3065 Université Jean Monnet, Saint Etienne, Service de Médecine et Thérapeutique, Unite de Pharmacologie Clinique, CHU Saint Etienne, France
    Thromb Haemost 107:1151-60. 2012
    ..5 mg after major orthopaedic surgery in renally impaired patients. It shows that these patients constitute a very elderly and fragile population...
  7. ncbi Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery
    Xavier Delavenne
    Thrombosis Research Group EA 3065, University Jean Monnet, 42023, Saint Etienne, France
    Eur J Clin Pharmacol 68:1403-10. 2012
    ..5 mg. As the drug is mainly eliminated by the kidneys, a reduced dosage (1.5 mg once daily) was developed for patients with renal impairment...
  8. ncbi Investigation of drug-drug interactions between clopidogrel and fluoxetine
    Xavier Delavenne
    Laboratoire de Pharmacologie Toxicologie, CHU Saint Etienne, F 42055, Saint Etienne, France Université de Lyon, F 42023, Saint Etienne, France Groupe de Recherche sur la Thrombose, EA3065, Universite de Saint Etienne, Jean Monnet, F 42023, Saint Etienne, France
    Fundam Clin Pharmacol 27:683-9. 2013
    ..9 and 22.4% lower after fluoxetine co-administration. The platelet reactivity index measured by the flow cytometric VASP method was 36.8% lower when clopidogrel was administered in conjunction with fluoxetine...
  9. pmc Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry
    Laurent Bertoletti
    Thrombosis Research Group, EA3065, University Saint Etienne, Jean Monnet, Saint Etienne F 42023, France
    Respir Res 14:75. 2013
    ..As it may induce therapeutic modifications, we evaluated the influence of the initial VTE presentation on the 3-month outcomes in COPD patients...
  10. doi Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice
    Xavier Delavenne
    Thrombosis Research Group EA 3065, University Jean Monnet, Saint Etienne, France
    Thromb Haemost 104:252-60. 2010
    ..A body weight less than 50 kg and moderate renal failure increased drug exposure. Although the population pharmacokinetic model of fondaparinux was described, this one requires to be validated in everyday practice...
  11. doi Fondaparinux for the treatment of superficial-vein thrombosis in the legs
    Herve Decousus
    INSERM CIE3, F 42055, EA3065 Université Jean Monnet, and Service de Médecine et Thérapeutique, Centre Hôpitalier Universitaire Saint Etienne, Hopital Nord, Saint Etienne, France
    N Engl J Med 363:1222-32. 2010
    ....
  12. pmc A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin
    Xavier Delavenne
    Laboratoire de Pharmacologie Toxicologie, University Hospital of Saint Etienne, Saint Etienne, France
    Br J Clin Pharmacol 76:107-13. 2013
    ..The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp...
  13. ncbi Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis
    Patrick Mismetti
    Thrombosis Research Group, Clinical Pharmacology Department, University Hospital Bellevue, F 42055 Saint Etienne, France
    Chest 128:2203-10. 2005
    ..We estimated the efficacy and safety of enoxaparin vs UFH in patients with proximal DVT with/without symptomatic PE using a meta-analysis of individual data from randomized controlled trials...
  14. doi A randomized double-blind trial of upward progressive versus degressive compressive stockings in patients with moderate to severe chronic venous insufficiency
    Serge Couzan
    Clinique Mutualiste, Saint Etienne, France
    J Vasc Surg 56:1344-1350.e1. 2012
    ....
  15. doi Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women
    Celine Chauleur
    Gynaecology Obstetrics Department, EA3065 Thrombosis Research Group, University Hospital, 42055 Saint Etienne Cedex 2, France
    Thromb Res 122:478-84. 2008
    ..Our objective was to assess whether treatment based on risk score is feasible in these women...
  16. ncbi Thrombophilia and risk of venous thrombosis in patients with cancer
    Herve Decousus
    University Hospital, Saint Etienne, France
    Thromb Res 120:S51-61. 2007
    ..Studies designed to assess the value of thromboprophylaxis in high-risk patients, including thrombophilic patients, with long-term central venous catheters may be valuable...
  17. ncbi A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism
    Patrick Mismetti
    Thrombosis Research Group, CIC EC, Clinical Pharmacology Department, University Hospital, Saint Etienne, France
    Chest 131:223-9. 2007
    ..The immediate and long-term clinical events associated with the placement and removal of a retrievable filter (ALN filter; ALN Implants Chirurgicaux; Ghisonaccia, France) remain largely unknown...
  18. ncbi Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis
    Sara Quenet
    Clinical Pharmacology Department, University Hospital Bellevue, Saint Etienne, France
    J Vasc Surg 38:944-9. 2003
    ..Superficial vein thrombosis may be complicated with venous thromboembolism. We examined factors predictive of venous thromboembolism in superficial vein thrombosis, which, to our knowledge, had not been prospectively studied before...
  19. pmc Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation
    Jean Christophe Lega
    Département de Médecine Interne et Vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Lyon, France Groupe de Recherche sur la Thrombose, EA3065, Universite de Saint Etienne, Jean Monnet, Saint Etienne, France
    PLoS ONE 9:e91398. 2014
    ..The aim of this meta-analysis was to determine the consistency of treatment effects of NOAC irrespective of age, comorbidities, or prior VKA exposure...
  20. doi PK evaluation of fondaparinux sodium for the treatment of thrombosis
    Xavier Delavenne
    Université Jean Monnet, EA3065, F 42023 Saint Etienne, France
    Expert Opin Drug Metab Toxicol 10:269-77. 2014
    ..Fondaparinux sodium (pentasaccharide) was the first of a new class of antithrombotic agents developed for the prevention and treatment of venous thromboembolism (VTE), blocking thrombin generation by selectively inhibiting factor Xa...
  21. doi Prevalence of poor biological response to clopidogrel: a systematic review
    Nora Mallouk
    Universite de Lyon, EA3065, Université Jean Monnet, Saint Etienne, France
    Thromb Haemost 107:494-506. 2012
    ..This meta-analysis shows that the prevalence of poor biological response depends on the assay employed, the cut-off value and on various unidentified additional factors...
  22. doi UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma
    Xavier Delavenne
    Laboratory of Pharmacology and Toxicology, University Hospital, F 42055 Saint Etienne, France
    J Pharm Biomed Anal 58:152-6. 2012
    ..3% and accuracy was within 93.8% and 108.8% for all QC levels (5, 75 and 400 μg/L). The lower limit of quantification was 2 μg/L. Total analysis time was to 10 min including sample preparation...
  23. ncbi [Booster study: comparative evaluation of a new concept of elastic stockings in mild venous insufficiency]
    Serge Couzan
    Clinique Mutualiste, Saint Etienne, France
    Presse Med 38:355-61. 2009
    ....
  24. ncbi Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials
    Paul Zufferey
    Anesthesiology and Intensive Care Department, University Hospital of Saint Etienne, France
    Thromb Haemost 90:654-61. 2003
    ..03). These findings are tentative because the comparisons are across trials, but nevertheless suggest that the different LMWH regimens currently recommended are effective and safe...
  25. ncbi Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial
    Patrick Mismetti
    Thrombosis Research Group Clinical Pharmacology Department, University Hospital Saint Etienne, Clinique Mutualiste La Digonnière, France
    Haematologica 88:67-73. 2003
    ..Vitamin K antagonists and low-molecular-weight heparins have been recommended in this setting, but their relative benefit-to-risk ratios have never been compared...
  26. ncbi Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis
    B Tardy-Poncet
    Laboratoire d Hematologie, Hopital Nord, France
    J Thromb Haemost 1:507-10. 2003
    ..7% of controls and in 11.0% of patients. TFPI resistance was associated with an almost threefold increase in the risk of thrombosis and could therefore represent a novel hemostatic risk factor for venous thrombosis...
  27. ncbi Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid
    X Delavenne
    Faculte de Medecine, Université Jean Monnet, EA3065, Saint Etienne, France
    Fundam Clin Pharmacol 23:127-35. 2009
    ..No covariate, including antibiotic treatment effect, significantly affected PT. Drug-drug interaction was demonstrated at the PK level, without any PD corollary...
  28. doi [Dabigatran: clinical pharmacology]
    P Mismetti
    Groupe de Recherche sur la Thrombose, EA 3065, CIE3, CHU de Saint Etienne, Université Jean Monnet, 42 055 Saint Etienne, France
    Ann Fr Anesth Reanim 28:S8-14. 2009
    ..From this study in AF patients, a dose regimen of 150 mg bid has been chosen to be evaluated for the treatment of VTE. No strong signal for a potential liver toxicity was shown during these studies...
  29. doi Tranexamic acid in hip fracture surgery: a randomized controlled trial
    P J Zufferey
    Department of Anaesthesiology and Intensive Care, University Hospital of Saint Etienne, 42055 Saint Etienne Cedex 02, France
    Br J Anaesth 104:23-30. 2010
    ..Hip fracture surgery may be associated with substantial blood loss. This study was designed to assess the efficacy and safety of the use of tranexamic acid in hip fracture surgery for the reduction of erythrocyte transfusion...
  30. doi Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study
    Herve Decousus
    University Hospital, Saint Etienne, France
    Ann Intern Med 152:218-24. 2010
    ..Superficial venous thrombosis (SVT) is perceived to have a benign prognosis...
  31. ncbi [Is very old age a prognostic factor for outcome after a first stroke?]
    P Calmels
    Service de Medecine Physique et de Readaptation, Hopital Bellevue, CHU de Saint Etienne, 42055 Saint Etienne Cedex 02, France
    Ann Readapt Med Phys 48:675-81. 2005
    ..To determine whether very old age, older than 80 years, after a stroke is a significant predictor of mortality, orientation to a specific care pathway after the acute phase and functional status at 6 months after the stroke...
  32. ncbi Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
    Paul Zufferey
    Department of Anesthesiology and Intensive Care and EA3065, Thrombosis Research Group, University Hospital of Saint Etienne, Saint Etienne, France
    Anesthesiology 105:1034-46. 2006
    ..Although the results suggest that aprotinin and tranexamic acid significantly reduce allogeneic erythrocyte transfusion, further evaluation of safety is required before recommending the use of antifibrinolytics in orthopedic surgery...
  33. doi Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite
    Xavier Delavenne
    Laboratory of Pharmacology and Toxicology, University Hospital, Saint Etienne, France
    J Sep Sci 33:1968-72. 2010
    ..The present method was successfully applied to a clopidogrel active metabolite pharmacokinetic study following oral administration to healthy volunteers...
  34. doi Lipoprotein (a), birth weight and neonatal stroke
    Cyrille Renaud
    Groupe de Recherche sur la Thrombose, EA 3065, Université Saint Etienne, Saint Etienne, France
    Neonatology 98:225-8. 2010
    ..Elevated lipoprotein (Lp) (a) is the most common genetically determined risk factor found in babies with perinatal ischemic stroke. The influence of maternal Lp(a) has not been studied extensively to date...
  35. ncbi [Meta-analyses or megatrials: same level of proof?]
    Patrick Mismetti
    Unite de Pharmacologie Clinique, Service de Médecine Interne et Thérapeutique, EA3065, CIE3, Centre Hospitalier Universitaire, Saint Etienne
    Presse Med 36:524-30. 2007
    ..Prospective meta-analyses or those planned before clinical trials can help to limit data heterogeneity by making study protocols less varied (treatment, follow-up, evaluation, etc.)...
  36. doi Cystatin C-based equations in renal transplantation: moving toward a better glomerular filtration rate prediction?
    Nicolas Maillard
    Service de Nephrologie, Dialyse, Transplantation Renale, Laboratoires d Explorations Fonctionnelles Rénales, Saint Etienne, France
    Transplantation 85:1855-8. 2008
    ..95, 95% CI 0.91-1) than for the MDRD equation (0.76, 95% CI 0.67-0.85). These data confirm that cystatin C as a GFR marker offers significant advantages over creatinine in renal transplantation...
  37. ncbi Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery
    P Mismetti
    Thrombosis Research Group, Clinical Pharmacology Unit, University Hospital, Saint-Etienne and Medibridge Clinical Research, Velizy, France
    Br J Surg 88:913-30. 2001
    ..LMWH seems to be as effective and safe as UFH. Determination of the optimal dose regimen of LMWH for this indication requires further investigation...
  38. pmc Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old
    A Berges
    Clinical Pharmacology Department, Thrombosis Research Group EA3065, University Hospital of Saint Etienne, Saint Etienne, France
    Br J Clin Pharmacol 64:428-38. 2007
    ..The PROPHRE.75 study was conducted to estimate the distribution parameters of anti-Xa activity in the elderly...
  39. doi [Rivaroxaban: clinical pharmacology]
    P Mismetti
    Groupe de Recherche sur la Thrombose, EA 3065 CIE3, Unite de recherche clinique, de l innovation et de Pharmacologie, CHU de Saint Etienne, Université Jean Monnet, 42055 Saint Etienne, France
    Ann Fr Anesth Reanim 27:S16-21. 2008
    ..No strong signal for a potential liver toxicity was shown during these 6 phases II...
  40. ncbi Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery
    S Laporte
    Clinical Pharmacology Unit, Thrombosis Research Group, University Hospital Saint Etienne Bellevue, F 42055 Saint Etienne cedex 02, France
    Eur J Pharm Sci 8:119-25. 1999
    ..The inter-individual variability (expressed in coefficient of variation) of these parameters are high, especially with regard to the apparent volume (92%), but no other available covariate was found to explain this variability...
  41. ncbi The location of deep-vein thrombosis as a predictive factor for recurrence and cancer discovery after proximal deep-vein thrombosis
    Silvy Laporte
    Haematologica 88:ELT08. 2003
  42. ncbi Thrombosis prophylaxis in cancer patients with a central venous catheter
    Silvy Laporte
    Arch Intern Med 164:459; author reply 459-60. 2004
  43. ncbi Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly
    Brigitte Tranchand
    Centre Léon Bérard EA Therapeutic Targeting in Oncology, Lyon, France
    Crit Rev Oncol Hematol 48:199-214. 2003
    ..The so-called "population modeling" approach renders such studies feasible by allowing the analysis of PK-PD relationships from sparse observational data...
  44. ncbi Prognostic factors in acute respiratory distress syndrome: a retrospective multivariate analysis including prone positioning in management strategy
    Christophe Venet
    Polyvalent Intensive Care Unit, Bellevue University Hospital, 42055, Saint Etienne Cedex 2, France
    Intensive Care Med 29:1435-41. 2003
    ..To investigate the prognostic factors in acute respiratory distress syndrome (ARDS) patients focusing on the use of prone positioning (PP)...
  45. ncbi Thromboprophylaxis in acute medical patients: need for an implementation strategy
    Patrick Mismetti
    Haematologica 87:673-5. 2002
  46. ncbi Intravenous thrombolytic therapy in patients with phlegmasia caerulea dolens
    Bernard Tardy
    Haematologica 91:281-2. 2006
    ..Intravenous thrombolysis should be seriously considered in patients with PCD...